|
|
| Home | Stock Market Blogs | Financial Tools | Sign Up Free | |
| Cytomedix, Inc. | |
||||||||||||||||||||||||||||||||||||||||||||||||||||
| Cytomedix, Inc. | |||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| GTF | Last: $0.595 ($-0.005) | Volume: 49,480 | Last Trade: 8/5/2010 4:15:10 PM | ||||||||||||||||||||||||||||||||||||||||||||||||||
| Today
Today | Last 7 Days | 1 Month | 3 Month | 6 Month | 1 Year |
|
||||||||||||||||||||||||||||||||||||||||||||||||||||
| Cytomedix, Inc. Profile | |||||||||||||||||||||||||||||||||||||||||||||||||||||
| Co. is a biotechnology company whose business model is premised upon developing, producing, and licensing autologous cellular therapies (i.e., therapies using the patient's own body products) for the treatment of chronic non-healing wounds using its propriety platelet gel and related product therapies. To create the proprietary platelet gel product, the patient's own platelets and other essential blood components for the healing process are separated through centrifugation and formed into a gel (the "AutoloGel ") that is topically applied to a wound under the direction of a physician. | |||||||||||||||||||||||||||||||||||||||||||||||||||||
| Cytomedix, Inc. News & Press Releases | |||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Cytomedix Reports First Quarter Financial Results ROCKVILLE, Md., May 17, 2010 (GLOBE NEWSWIRE) -- Cytomedix, Inc. (NYSE Amex:GTF) (the "Company"), a leading developer of biologically active regenerative th... [more] GTF up 22.22% after director buy ( EMAILWIRE.COM , April 30, 2010 ) Boston, MA - InsiderCow.com: JORDEN DAVID EMERSON, director of CYTOMEDIX INC (AMEX: GTF) bought 39000 shares of GTF from the open market on 2010-04-29 according to an SEC filing reported by insidercow.com at 2010-04-... [more] Cytomedix Acquires Angel Whole Blood Separation System and activAT Autologous Thrombin Processing Ki Synergistic Products Expand Customer Base, Bring $5 Million in Annual Sales Conference Call Begins April 13th at 10:... [more] Cytomedix Announces Going Concern Qualification ROCKVILLE, Md., April 12, 2010 (GLOBE NEWSWIRE) -- Cytomedix, Inc. (NYSE Amex:GTF) announced today that its audited financial statements for the fiscal year... [more] Cytomedix Reports Fourth Quarter and Full Year Financial Results ROCKVILLE, Md., March 29, 2010 (GLOBE NEWSWIRE) -- Cytomedix, Inc. (NYSE Amex:GTF), a leading developer of biologically active regenerative therapies for wo... [more] Cytomedix Reports Third Quarter Financial Results ROCKVILLE, Md., Nov. 11, 2009 (GLOBE NEWSWIRE) -- Cytomedix, Inc. (NYSE Amex: GTF), a leading developer of biologically active regenerative therapies for wo... [more] Cytomedix Appoints Martin P. Rosendale Executive Vice President ... Primenewswire (press release): Cytomedix, Inc. ( AMEX:GTF ) today announced the appointment of Martin P. Rosendale, an industry veteran ... |
|||||||||||||||||||||||||||||||||||||||||||||||||||||
| Home | Blogs | Savings Calculator | Tools | Contact Us | Disclosure | Site Map | Sign Up | Copyright © 2013 SmallCapWatch, LLC. |
| Never invest based soley on information from this website or our e-mail and IM alerts | |
